Trial Profile
Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Dec 2006
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 06 Dec 2006 Status change
- 19 Aug 2005 New trial record.